JP2009523460A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009523460A5 JP2009523460A5 JP2008551864A JP2008551864A JP2009523460A5 JP 2009523460 A5 JP2009523460 A5 JP 2009523460A5 JP 2008551864 A JP2008551864 A JP 2008551864A JP 2008551864 A JP2008551864 A JP 2008551864A JP 2009523460 A5 JP2009523460 A5 JP 2009523460A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- dom10
- ligand
- variable domain
- single variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003446 ligand Substances 0.000 claims 117
- 102000003816 Interleukin-13 Human genes 0.000 claims 70
- 108090000176 Interleukin-13 Proteins 0.000 claims 70
- 108060003951 Immunoglobulin Proteins 0.000 claims 53
- 102000018358 immunoglobulin Human genes 0.000 claims 53
- 125000003275 alpha amino acid group Chemical group 0.000 claims 33
- 102000004388 Interleukin-4 Human genes 0.000 claims 28
- 108090000978 Interleukin-4 Proteins 0.000 claims 28
- 229940028885 interleukin-4 Drugs 0.000 claims 28
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 17
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 17
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 16
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 15
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 15
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 102100020791 Interleukin-13 receptor subunit alpha-1 Human genes 0.000 claims 8
- 101710112663 Interleukin-13 receptor subunit alpha-1 Proteins 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 8
- 230000001629 suppression Effects 0.000 claims 8
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims 7
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 6
- 108020001507 fusion proteins Proteins 0.000 claims 6
- 102000037865 fusion proteins Human genes 0.000 claims 6
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 6
- 101001076430 Homo sapiens Interleukin-13 Proteins 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 102000019207 human interleukin-13 Human genes 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 239000013566 allergen Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 102000007562 Serum Albumin Human genes 0.000 claims 3
- 108010071390 Serum Albumin Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 229920001515 polyalkylene glycol Polymers 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 241000238876 Acari Species 0.000 claims 1
- 244000025254 Cannabis sativa Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 102000004559 Interleukin-13 Receptors Human genes 0.000 claims 1
- 108010017511 Interleukin-13 Receptors Proteins 0.000 claims 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 1
- 108010001831 LDL receptors Proteins 0.000 claims 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 241000282560 Macaca mulatta Species 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 102000007238 Transferrin Receptors Human genes 0.000 claims 1
- 108010033576 Transferrin Receptors Proteins 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 claims 1
- 239000000428 dust Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 102000055229 human IL4 Human genes 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
- 239000013573 pollen allergen Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76170806P | 2006-01-24 | 2006-01-24 | |
| PCT/GB2007/000228 WO2007085815A2 (en) | 2006-01-24 | 2007-01-24 | Ligands that bind il-4 and/or il-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009523460A JP2009523460A (ja) | 2009-06-25 |
| JP2009523460A5 true JP2009523460A5 (https=) | 2009-11-05 |
Family
ID=38028503
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008551864A Pending JP2009523460A (ja) | 2006-01-24 | 2007-01-24 | Ｉｌ−４および／またはｉｌ−１３に結合するリガンド |
| JP2008551863A Pending JP2009523459A (ja) | 2006-01-24 | 2007-01-24 | 天然の連結部を含有する融合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008551863A Pending JP2009523459A (ja) | 2006-01-24 | 2007-01-24 | 天然の連結部を含有する融合タンパク質 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20110159003A1 (https=) |
| EP (1) | EP1976882A2 (https=) |
| JP (2) | JP2009523460A (https=) |
| KR (1) | KR20080098382A (https=) |
| CN (1) | CN101578298A (https=) |
| AU (1) | AU2007209202A1 (https=) |
| BR (1) | BRPI0710572A2 (https=) |
| CA (1) | CA2636854A1 (https=) |
| CR (1) | CR10179A (https=) |
| EA (1) | EA200801515A1 (https=) |
| IL (1) | IL192572A0 (https=) |
| MA (1) | MA30175B1 (https=) |
| NO (1) | NO20082942L (https=) |
| TW (2) | TW200740843A (https=) |
| WO (1) | WO2007085815A2 (https=) |
| ZA (1) | ZA200806202B (https=) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2421464C2 (ru) | 2005-10-21 | 2011-06-20 | Новартис Аг | Человеческие антитела к il-13 и их терапевтическое применение |
| WO2009138413A1 (en) * | 2008-05-15 | 2009-11-19 | Domantis Limited | Single domain antibodies that bind il-13 |
| JP2009536527A (ja) * | 2006-05-09 | 2009-10-15 | ジェネンテック・インコーポレーテッド | 最適化されたスキャフォールドを備えた結合ポリペプチド |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| EP2195342A1 (en) * | 2007-09-07 | 2010-06-16 | Ablynx N.V. | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
| EP2036980A1 (de) * | 2007-09-14 | 2009-03-18 | Gruber, Jens | Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel |
| EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| AU2017201007B2 (en) * | 2007-10-15 | 2018-12-13 | Sanofi | Antibodies that bind IL-4 and/or IL-13 and their uses |
| CN102131827A (zh) * | 2007-12-13 | 2011-07-20 | 葛兰素集团有限公司 | 用于肺部传递给药的组合物 |
| WO2009089295A2 (en) | 2008-01-07 | 2009-07-16 | Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Anti-hiv domain antibodies and method of making and using same |
| EP2631302A3 (en) * | 2008-03-31 | 2014-01-08 | Genentech, Inc. | Compositions and methods for treating and diagnosing asthma |
| EP2268668A1 (en) | 2008-04-17 | 2011-01-05 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
| HRP20170374T1 (hr) * | 2008-09-26 | 2017-05-05 | Ucb Biopharma Sprl | Biološki proizvodi |
| BRPI0919714A2 (pt) * | 2008-10-21 | 2015-12-08 | Domantis Ltd | domínio variável único de imunoglobulina, polipeptídeo isolado, ligante, ácido nucleico, vetor, célula hospedeira, e, método para produzir um polipeptídeo |
| BRPI0919881B1 (pt) | 2008-10-31 | 2021-09-08 | Centocor Ortho Biotech Inc | Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação |
| AU2008364461A1 (en) * | 2008-11-26 | 2010-06-03 | Domantis Limited | Ligands that bind IL-13 |
| US8858940B2 (en) | 2008-12-10 | 2014-10-14 | Ablynx N.V. | Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis |
| US9394374B2 (en) | 2009-05-28 | 2016-07-19 | Glaxo Group Limited | Antigen-binding proteins |
| EP2435481A1 (en) * | 2009-05-28 | 2012-04-04 | Glaxo Group Limited | Il-13 binding protein |
| JP2012532620A (ja) * | 2009-07-16 | 2012-12-20 | グラクソ グループ リミテッド | 改良型抗血清アルブミン結合単一可変ドメイン |
| BR112012001977A2 (pt) * | 2009-07-29 | 2017-01-31 | Glaxo Group Ltd | domínio variável único de imunoglobulina, polipeptídeo isolado, ligante, proteína de fusão, ácido nucleico isolado, molécula de ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir um polipeptídeo e para tratar e/ou prevenir uma condição, composição farmacêutica, uso de um domínio variável único, e, dispositivo de dispensação pulmonar. |
| CN102781959A (zh) | 2010-02-05 | 2012-11-14 | 埃博灵克斯股份有限公司 | 能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽 |
| PT3501499T (pt) * | 2010-02-11 | 2022-11-22 | Ablynx Nv | Métodos e composições para a preparação de aerossóis |
| EP3569256B1 (en) | 2010-04-30 | 2022-06-15 | Janssen Biotech, Inc. | Stabilized fibronectin domain compositions, methods and uses |
| JP6062375B2 (ja) | 2011-01-06 | 2017-01-18 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｔｇｆ−ベータ受容体ｉｉに結合するリガンド |
| US20130344074A1 (en) | 2011-03-16 | 2013-12-26 | Sanofi | Uses of a dual v region antibody-like protein |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| BR112013026828A2 (pt) | 2011-04-21 | 2016-11-29 | Bristol Myers Squibb Co | polipeptídeos de anticorpo que antagonizam cd40 |
| EP2761066B1 (en) | 2011-09-27 | 2018-12-05 | Janssen Biotech, Inc. | Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces |
| US10481164B2 (en) * | 2012-03-26 | 2019-11-19 | Amgen Inc. | Method for using light scattering in real time to directly monitor and control impurity removal in purification processes |
| MX2014016038A (es) | 2012-06-22 | 2015-08-14 | Cytomx Therapeutics Inc | Anticuerpos de reaccion cruzada anti - jagged 1 / jagged 2, anticuerpos anti - jagged activables y metodos para uso de los mismos. |
| JP6306588B2 (ja) | 2012-08-21 | 2018-04-04 | サノフィ・バイオテクノロジー | Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法 |
| EP3165535B1 (en) * | 2012-08-22 | 2019-05-15 | Mogam Biotechnology Research Institute | Screening and engineering method of super-stable immunoglobulin variable domains and their uses |
| EP3828203B1 (en) * | 2013-12-17 | 2024-04-24 | MHS Care - Innovation LLC | Compositions and methods for treating fatty tissue buildup |
| US11066467B2 (en) | 2013-12-17 | 2021-07-20 | Mhs Care-Innovation Llc | Compositions and methods for treating ischemic heart disease |
| IL315136A (en) * | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| WO2015134988A1 (en) | 2014-03-07 | 2015-09-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
| EP3129497B1 (en) * | 2014-04-11 | 2021-09-08 | Novartis AG | Methods of selectively treating asthma using il-13 antagonists |
| PL3204095T3 (pl) | 2014-10-10 | 2019-10-31 | Ablynx Nv | Urządzenie do inhalacji do stosowania w terapii aerozolowej chorób układu oddechowego |
| RU2017115670A (ru) | 2014-10-10 | 2018-11-15 | Аблинкс Н.В. | Лечение инфекции рсв |
| CA3246946A1 (en) | 2014-11-14 | 2025-11-29 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| AU2015366284B2 (en) | 2014-12-19 | 2021-07-22 | Ablynx N.V. | Cysteine linked nanobody dimers |
| CA3022697A1 (en) | 2016-05-02 | 2017-11-09 | Ablynx Nv | Treatment of rsv infection |
| JP6293829B2 (ja) * | 2016-08-05 | 2018-03-14 | モガム インスティチュート フォー バイオメディカル リサーチＭＯＧＡＭ Ｉｎｓｔｉｔｕｔｅ ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ | 安定化された免疫グロブリン可変ドメイン選別方法及び選別されたドメインの応用 |
| WO2018099968A1 (en) | 2016-11-29 | 2018-06-07 | Ablynx N.V. | Treatment of infection by respiratory syncytial virus (rsv) |
| WO2018111976A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Pd-l1 binding fibronectin type iii domains |
| US10611823B2 (en) | 2016-12-14 | 2020-04-07 | Hanssen Biotech, Inc | CD137 binding fibronectin type III domains |
| NZ754187A (en) | 2016-12-14 | 2026-02-27 | Janssen Biotech Inc | Cd8a-binding fibronectin type iii domains |
| KR102694419B1 (ko) | 2017-10-30 | 2024-08-09 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법 |
| CN108855003B (zh) * | 2018-06-28 | 2021-01-05 | 南开大学 | 一种用于清除血液中炎性因子的免疫吸附剂及其制备方法 |
| CN110746507B (zh) | 2018-12-25 | 2020-06-26 | 江苏荃信生物医药有限公司 | 抗人白介素4受体α单克隆抗体及其应用 |
| CN114126646B (zh) * | 2019-02-27 | 2025-05-30 | 浙江纳米抗体技术中心有限公司 | 基于序列的高通量方法产生骆驼抗体以高分辨率覆盖广泛表位 |
| WO2021011614A1 (en) | 2019-07-16 | 2021-01-21 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
| WO2021076574A2 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Fn3 domain-sirna conjugates and uses thereof |
| CN114786682B (zh) | 2019-10-14 | 2024-07-16 | Aro生物疗法公司 | 结合cd71的纤维粘连蛋白iii型结构域 |
| WO2021076543A1 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Epcam binding fibronectin type iii domains |
| JP2023523600A (ja) | 2020-04-22 | 2023-06-06 | マブウェル （シャンハイ） バイオサイエンス カンパニー リミテッド | ヒトプログラム細胞死リガンド１（ｐｄ－ｌ１）を標的とする単一可変ドメイン抗体およびその誘導体 |
| KR20230008157A (ko) * | 2020-05-06 | 2023-01-13 | 드래곤플라이 쎄라퓨틱스, 인크. | 항체 표적화 clec12a 및 이의 사용 |
| MX2022013944A (es) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| BR112023021318A2 (pt) | 2021-04-14 | 2023-12-19 | Aro Biotherapeutics Company | Conjugados de domínio fn3-sirna e usos dos mesmos |
| CA3214552A1 (en) | 2021-04-14 | 2022-10-20 | Russell C. Addis | Cd71 binding fibronectin type iii domains |
| US20240117030A1 (en) * | 2022-03-03 | 2024-04-11 | Pfizer Inc. | Multispecific antibodies and uses thereof |
| EP4573119A1 (en) * | 2022-08-17 | 2025-06-25 | Institut National de la Santé et de la Recherche Médicale | Improved anti-albumin nanobodies and their uses |
| JP7668943B2 (ja) * | 2023-08-30 | 2025-04-25 | ファイザー・インク | 多重特異性抗体およびその使用 |
| JP2025036273A (ja) * | 2023-08-30 | 2025-03-14 | ファイザー・インク | 多重特異性抗体およびその使用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869620A (en) * | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| ATE171472T1 (de) * | 1992-02-19 | 1998-10-15 | Schering Corp | Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4 |
| US5596072A (en) * | 1992-08-21 | 1997-01-21 | Schering Corporation | Method of refolding human IL-13 |
| US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
| US7175988B2 (en) * | 2001-02-09 | 2007-02-13 | Human Genome Sciences, Inc. | Human G-protein Chemokine Receptor (CCR5) HDGNR10 |
| ES2263984T3 (es) * | 2002-06-28 | 2006-12-16 | Domantis Limited | Ligandos doble-especificos con una vida media serica aumentada. |
| AU2003290330A1 (en) * | 2002-12-27 | 2004-07-22 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| SG10201404273QA (en) * | 2003-12-23 | 2014-10-30 | Genentech Inc | Novel anti-il 13 antibodies and uses thereof |
| AU2005219837A1 (en) * | 2004-02-27 | 2005-09-15 | Regeneron Pharmaceuticals, Inc. | IL-4/IL-13 sepecific polypetides and therapeutic uses thereof |
| AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| TWI307630B (en) * | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| US7569586B2 (en) * | 2004-08-16 | 2009-08-04 | Theravance, Inc. | Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
-
2007
- 2007-01-24 JP JP2008551864A patent/JP2009523460A/ja active Pending
- 2007-01-24 CA CA002636854A patent/CA2636854A1/en not_active Abandoned
- 2007-01-24 WO PCT/GB2007/000228 patent/WO2007085815A2/en not_active Ceased
- 2007-01-24 BR BRPI0710572-0A patent/BRPI0710572A2/pt not_active IP Right Cessation
- 2007-01-24 TW TW096102774A patent/TW200740843A/zh unknown
- 2007-01-24 JP JP2008551863A patent/JP2009523459A/ja active Pending
- 2007-01-24 CN CNA2007800097556A patent/CN101578298A/zh active Pending
- 2007-01-24 AU AU2007209202A patent/AU2007209202A1/en not_active Abandoned
- 2007-01-24 US US12/223,005 patent/US20110159003A1/en not_active Abandoned
- 2007-01-24 EA EA200801515A patent/EA200801515A1/ru unknown
- 2007-01-24 KR KR1020087020811A patent/KR20080098382A/ko not_active Ceased
- 2007-01-24 TW TW096102778A patent/TW200804593A/zh unknown
- 2007-01-24 EP EP07705003A patent/EP1976882A2/en not_active Withdrawn
-
2008
- 2008-05-15 US US12/152,903 patent/US20090060916A1/en not_active Abandoned
- 2008-07-02 NO NO20082942A patent/NO20082942L/no not_active Application Discontinuation
- 2008-07-02 IL IL192572A patent/IL192572A0/en unknown
- 2008-07-16 ZA ZA200806202A patent/ZA200806202B/xx unknown
- 2008-07-24 CR CR10179A patent/CR10179A/es unknown
- 2008-07-25 MA MA31143A patent/MA30175B1/fr unknown
-
2009
- 2009-05-13 US US12/992,718 patent/US20120093830A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009523460A5 (https=) | ||
| JP7817994B2 (ja) | Ｉｌ－１３およびｏｘ４０ｌを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド | |
| JP7641968B2 (ja) | Ｉｌ－１３およびｔｓｌｐを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド | |
| RU2427589C2 (ru) | Антитела против интерлейкина-13 человека и их применение | |
| CN113527485B (zh) | 抗人白细胞介素-4受体α抗体及其制备方法和应用 | |
| EP3808774B1 (en) | Human il-4r binding antibody, antigen binding fragment thereof, and medical use thereof | |
| JP2008502366A5 (https=) | ||
| CN102482352B (zh) | 抗il-17br的抗体 | |
| JP2009519011A5 (https=) | ||
| JP2009517069A5 (https=) | ||
| CN110357963A (zh) | 抗人st2抗体及其用途 | |
| JP7608592B2 (ja) | ヘテロ二量体Ｆｃ融合タンパク質、並びに関連の組成物、用途及び方法 | |
| WO2022117079A1 (zh) | 结合胸腺基质淋巴细胞生成素的抗体及其应用 | |
| WO2021082573A1 (zh) | 抗il-4r单域抗体及其应用 | |
| WO2024130394A1 (en) | Multivalent and multispecific cytokine antagonists | |
| CN116783214A (zh) | 包含靶向il-13和ox40l的免疫球蛋白单可变结构域的多肽 | |
| CN117843776B (zh) | 抗体分子、核酸、制药用途及炎性疾病治疗方法 | |
| RU2825460C1 (ru) | Антитела к TSLP человека и их применение | |
| CN119855828A (zh) | 抗TfR1的单域抗体及其用途 | |
| WO2025221933A1 (en) | Antibodies and polypeptides comprising variant fc regions | |
| HK40096780A (zh) | 抗人il-4ra的抗体及其用途 | |
| HK1170745B (en) | Antibodies against il-17br |